论文部分内容阅读
目的:探讨乳腺癌组织SULT1E1的表达,并分析其与临床病理学特征及预后因素的相关性。方法:采用免疫组织化学二步法检测129例乳腺癌组织和癌旁正常组织SULT1E1的表达情况,应用Kaplan-Meier法行单因素生存分析SULT1E1的表达与临床病理学特征及预后的关系。结果:乳腺癌组织中SULT1E1的阳性表达率(25.6%)明显低于癌旁组织(45.0%),差异有统计学意义,P<0.05;SULT1E1的表达与乳腺癌患者年龄、肿瘤大小、淋巴结转移和病理类型以及是否有远处转移等无明显相关性,P>0.05。Kaplan-Meier生存分析曲线显示,SULT1E1阳性表达患者的术后无复发生存率较阴性表达患者明显增高,χ2=4.943,P<0.05。结论:乳腺癌组织SULT1E1低表达者提示预后不佳,SULT1E1检测有可能成为判断乳腺癌分期和预后的重要分子标志,并成为重要的预后因素。
Objective: To investigate the expression of SULT1E1 in breast cancer and analyze its correlation with clinical pathological features and prognostic factors. Methods: The expression of SULT1E1 was detected by immunohistochemical two-step method in 129 cases of breast cancer and adjacent normal tissues. The relationship between the expression of SULT1E1 and clinicopathological features and prognosis was analyzed by Kaplan-Meier method. Results: The positive expression rate of SULT1E1 in breast cancer was significantly lower than that in paracancerous tissues (45.0%, P <0.05). The expression of SULT1E1 was correlated with the age, tumor size, lymph node metastasis And pathological types and whether there is no distant metastasis and other significant correlation, P> 0.05. Kaplan-Meier survival analysis showed that patients with SULT1E1-positive expression had significantly higher postoperative recurrence-free survival than those with negative expression (χ2 = 4.943, P <0.05). Conclusion: The low expression of SULT1E1 in breast cancer suggests poor prognosis. The detection of SULT1E1 may be an important molecular marker to determine the stage and prognosis of breast cancer and become an important prognostic factor.